Interestingly, in HER2-negative BC cell lines, activation through phosphorylation of HER2 made this biomarker recognizable by trastuzumab, a chemotherapeutic drug that targets the extracellular domain of the HER2 protein [168,169]. Here, ERBB2 is linked to breast cancer.